The Oregon Division of Financial Regulation announced Prescription Drug Price Transparency program updates

Oregon — The Oregon Division of Financial Regulation recently announced the following permanent rulemaking: ID 17-2026: Prescription Drug Price Transparency program updates

Rules: 836-200-0505, 836-200-0515, 836-200-0520, 836-200-0530, 836-200-0531, 836-200-0532, 836-200-0533, 836-200-0535, 836-200-0545, 836-200-0555

Summary: In addition to updating the rules to reflect the 2025 court decision, the department also clarified requirements, updated a reporting threshold, and added minor data collection points to allow program staff to verify accurate reporting. The changes to the rules include:

Adding a clarifying definition for “drug;”

Correction of internal references;

Reverting annual price increase reporting from voluntary to mandatory per court judgment;

Clarifying language about the timing of data reporting;

Adding examples of factors that may contribute to price increases;

Updating the threshold for reporting new prescription drugs; and,

Adding minor data collection points to allow for DPT program staff verification.

Filed: September 22, 2026

Effective: October 1, 2026